ATC Group: J05AB18 Molnupiravir

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AB18 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
5 J05AB18

Active ingredients in J05AB18

Active Ingredient

Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP).

Related product monographs

Document Type Information Source  
 LAGEVRIO Hard capsule MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

United States medicines

Medicines classified under this ATC code globally

Japan (JP)

New Zealand (NZ)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.